SAB Biotherapeutics, Inc.
SABS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $35,103 | $37,984 | $25,672 | $339,501 |
| - Cash | $8,898 | $56,566 | $15,047 | $33,207 |
| + Debt | $4,669 | $5,907 | $5,929 | $8,516 |
| Enterprise Value | $30,874 | -$12,675 | $16,554 | $314,810 |
| Revenue | $1,322 | $2,239 | $23,904 | $60,876 |
| % Growth | -40.9% | -90.6% | -60.7% | – |
| Gross Profit | -$3,470 | -$1,506 | $20,612 | $59,222 |
| % Margin | -262.4% | -67.3% | 86.2% | 97.3% |
| EBITDA | -$28,994 | -$38,133 | -$15,122 | -$15,196 |
| % Margin | -2,192.5% | -1,703.1% | -63.3% | -25% |
| Net Income | -$34,105 | -$42,194 | -$18,741 | -$17,145 |
| % Margin | -2,579% | -1,884.5% | -78.4% | -28.2% |
| EPS Diluted | -3.68 | -7.64 | -4.31 | -6.3 |
| % Growth | 51.8% | -77.3% | 31.6% | – |
| Operating Cash Flow | -$34,292 | -$25,119 | -$23,460 | $1,987 |
| Capital Expenditures | -$337 | -$197 | -$2,166 | -$10,944 |
| Free Cash Flow | -$34,629 | -$25,317 | -$25,626 | -$8,957 |